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Abstract
In this study, we established an in vitro organoid model of normal human ovarian surface epithelial (HOSE) cells.
The spheroids of these normal HOSE cells resembled epithelial inclusion cysts in human ovarian cortex, which are
the cells of origin of ovarian epithelial tumor. Because there are strong correlations between chronic inflammation
and the incidence of ovarian cancer, we used the organoid model to test whether protumor inflammatory cytokine
tumor necrosis factor α would induce malignant phenotype in normal HOSE cells. Prolonged treatment of tumor
necrosis factor α induced phenotypic changes of the HOSE spheroids, which exhibited the characteristics of pre-
cancerous lesions of ovarian epithelial tumors, including reinitiation of cell proliferation, structural disorganization, epi-
thelial stratification, loss of epithelial polarity, degradation of basement membrane, cell invasion, and overexpression
of ovarian cancer markers. The result of this study provides not only an evidence supporting the link between chronic
inflammation and ovarian cancer formation but also a relevant and novel in vitromodel for studying of early events of
ovarian cancer.
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Introduction
Ovarian cancer is the most lethal gynecological cancer in the United
States and Europe. A high mortality rate makes this disease a major
women’s health concern. Approximately 70% of patients whose con-
ditions are diagnosed with ovarian cancer will present at advanced
stages (FIGO stages III and IV), whereas the 5-year survival rate
for this group of patients is only 10% to 40% [1]. Unclear etiology
of ovarian cancer and incomplete understanding of the nature of
its precursor lesions are the major reasons for the slow development
of early detection markers and targeted therapy. In addition, lack
of transgenic mouse models that recapitulate clinical features of
early-stage ovarian cancer also makes study of early events of ovarian
cancer difficult.
Although all cell types in the human ovary (including epithelial,
stromal, and germ cells) may undergo tumor transformation, 80% to
90% of malignant ovarian tumors are originated from the single layer
of epithelial cells covering the ovaries [2]. In addition to the surface
epithelium of ovary, there are epithelial inclusion cysts that are
simply cysts lined by a single layer of epithelium and located in
the human ovarian cortex [3], which can be found in fetal and new-
born ovaries [4] but more frequently in the ovaries of aged women
[3,5]. Most importantly, the epithelial inclusion cysts have a greater
propensity to tumor development than the surface epithelium of the
ovary [5]. This may be due to the preferential location of the epithe-
lial inclusion cysts that are exposed to tumor-promoting factors in
the microenvironment of ovarian cortex [6].
In the past decade, epidemiological data suggested that chronic in-
flammation is associated with ovarian tumor development. Studies
showed that factors relating to inflammation of the ovarian surface
epithelium (OSE; such as asbestos and talc exposure, endometriosis,
and pelvis inflammatory diseases) are associated with an increased
risk for ovarian cancer [7–9]. Nevertheless, tubal ligation and hyster-
ectomy were shown to be the protective factors against ovarian cancer
because these procedures reduce the exposure of the OSE to inflam-
matory agents [7,10]. Latest statistics also showed that the use of
aspirin or other nonsteroidal anti-inflammatory drugs reduces the
risk of ovarian cancer [9,11].
Among inflammatory mediators, several cytokines (such as tumor
necrosis factor α (TNF-α), interleukin 1β (IL-1β), and IL-6) pro-
duced by activated innate immune cells have been shown to promote
tumor growth and progression [12]. The roles of cytokines in the
development of ovarian cancer have also been investigated previously.
Studies showed that TNF-α would particularly promote tumor pro-
gression, invasion, and metastasis of ovarian cancer cells [13–15].
However, the roles of TNF-α in tumor initiation in normal human
ovarian surface epithelial (HOSE) cells remain largely unknown.
Therefore, in this study, we have established an in vitro organoid
model of normal HOSE cells, which mimics ovarian inclusion cysts,
and used the model to test whether the inflammatory cytokine TNF-α
would induce malignant phenotype in normal HOSE cells.
Materials and Methods
Reagents
Recombinant human TNF-α was purchased from Calbiochem (La
Jolla, CA). Anti–Ki-67, anti-calretinin, and anti-CA125 antibodies
were obtained from Zymed (South San Francisco, CA); anti–cleaved
caspase 3 (Asp175) and anti–ezrin/radixin/moesin (ERM) were
obtained from Cell Signaling Technology (Beverly, MA); anti–claudin
4, anti–heparan sulfate proteoglycan (HSPG), and anti–matrix metallo-
proteinase 10 (MMP-10) were obtained from Lab Vision Corporation
(Fremont, CA); anti–cytokeratin AE1&3 and anti–Laminin V were
obtained from Chemicon International (Temecula, CA); anti-GM130
and ECAD were from BD Transduction Laboratories (Franklin Lakes,
NJ); anti–human collagen IV, anti–human epithelial membrane anti-
gen (EMA/MUC1), anti–human epithelial antigen (EpCAM) were
purchased from DakoCytomation (Carpinteria, CA).
Tissue Culture
Fragments of HOSE cells were detached with a SAFETEX sterile
cytology brush (Andwin Scientific, Warner Center, CA) from the sur-
face of grossly normal ovaries. The specimens were obtained with
consent from patients having surgery for benign gynecologic diseases.
The cells were cultured in Medium199/MCDB105 (Sigma, St. Louis,
MO) with 15% FBS for 1 week, then maintained in complete medium
with 10% FBS until confluent in a 25-cm2 flask. Normal HOSE cells
in the primary cultures were confirmed by their characteristic epithelial
morphology and immunofluorescent staining of cytokeratin (AE1&3)
and calretinin. First passages of primary cultures with more than 95%
of normal HOSE cells were used. Human papilloma virus (HPV)
E6/E7–immortalized HOSE cells (IHOSE1-15, 12, 636, and 642)
[16] and hTERT-immortalized HOSE cells (IOSE20, 21, and 25)
[17] were also used in this study.
Three-dimensional Organoid Model of Normal HOSE Cells
The method of our three-dimensional (3D) organoid model of
normal HOSE cells was modified from MCF-10A mammary epithe-
lial spheroid model as described by Debnath et al. [18]. Eight-well
glass-chambered slides (Nalge Nunc International, Naperville, IL)
were coated with growth factor–reduced Matrigel matrix without
phenol red (BD Biosciences, Bedford, MA) per well and left to solidify.
Primary culture of normal HOSE cells was trypsinized and resuspended
in complete medium with 10% FBS and 2% Matrigel. Twenty thou-
sand normal HOSE cells were seeded onto each Matrigel-coated well.
Complete medium with 2% Matrigel was replaced every 4 days. For
TNF-α treatment, 10 ng/ml of recombinant human TNF-αwas added
to the culture medium at day 4. TNF-α and fresh media were replaced
every 4 days, and the organoid cultures were harvested at day 40.
Immunofluorescent Staining
Control HOSE spheroids and TNF-α–treated cystic structures in
Matrigel were fixed in 2% paraformaldehyde. Fixed spheroids were
permeabilized with PBS containing 0.5% Triton X-100 and washed
three times with 0.1% Triton X-100 in PBS. The washed spheroids
were blocked with PBS containing 0.2% BSA and 10% normal goat
serum ( Jackson ImmunoResearch, West Grove, PA). Primary anti-
bodies were diluted in IF buffer (PBS containing 0.2% BSA and
1% normal goat serum) and incubated. Unbound primary antibodies
were removed by PBSwashing. Secondary antibodies coupled with Alexa
Fluor 647 (Molecular Probes, Eugene, OR) and Alexa Fluor 546 phal-
loidin (Molecular Probes) were diluted in IF buffer and incubated with
the spheroids. Unbound secondary antibodies were washed. The spher-
oids were then postfixed with 2% paraformaldehyde and counterstained
with 1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI) (Molecular
Probes). Microscopic images were captured and analyzed by Leica
DMIRE2 fluorescence microscope (Leica Microsystems, Bannockburn,
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IL) and OpenLab software (Improvision, Lexington, MA). Twenty
z-section images (0.5-μm interval) were taken from each spheroid. The
images were then deconvoluted by Volocity software (Improvision). For
epithelial inclusion cysts in human ovarian cortex, frozen sections (7 μm)
of normal ovaries were used for immunofluorescent staining.
Electronic Microscopy
Spheroids of normal HOSE cells were harvested at day 40, fixed in
2.5% glutaraldehyde in 0.1 M phosphate buffer, and processed for
transmission electron microscopy (TEM) analysis as described [7].
Diameter Measurement and Cell Proliferation
Assay of HOSE Spheroids
The longest diameter of each control HOSE spheroid and TNF-α–
treated cystic structures was measured by OpenLab software (Impro-
vision). The data were compared using nonparametric Mann-Whitney
U test. The level of critical significance was set at P < .05. The analyses
were performed using SPSS version 10.0 (SPSS, Inc., Chicago, IL). Cell
proliferation rates of HOSE cells in organoid cultures (days 7, 14,
and 40) were determined by CellTiter 96 nonradioactive cell prolifera-
tion assay (Promega, Madison, WI).
Semiquantitative and Real-time Reverse
Transcription–Polymerase Chain Reaction
Total RNA of control HOSE spheroids and TNF-α–treated cystic
structures was isolated by TriZOL reagent (Invitrogen) and subse-
quently purified by RNeasy Micro kit (Qiagen, Valencia, CA). The
quantity of the isolated RNA was determined by Quant-iT RiboGreen
Assay kit (Molecular Probes). Fifteen nanograms of total RNA was
then amplified and reverse-transcribed by Ovation Aminoallyl RNA
amplification and labeling system (NuGEN Technologies, Inc., San
Carlos, CA). A ten-fold dilution of amplified cDNAwas used for quan-
titative polymerase chain reaction (PCR). For semiquantitative reverse
transcription (RT)–PCR analysis of MMP and tissue inhibitor of
metalloproteinase (TIMP) genes, human MMP gene family I and II
MultiGene-12 RT-PCR profiling kits were used (SuperArray, Frederick,
MD). For real-time RT-PCR, probes and primer sets for human
COL41A, COX-2, CXCR4,DAB2, IL-1β, andMMP-10were obtained
from Taqman Gene Expression Assays (Applied Biosystems, Foster City,
CA). Human PPIA (cyclophilin A) was used as endogenous control.
Real-time PCR was performed by 7300 real-time PCR systems (Applied
Biosystems). All reactions were performed in triplicate. The transcrip-
tion level of each gene of the treated samples was compared with that
of control by 2(−ΔΔCT) calculation [19].
Cell Viability Assay
After treatment with TNF-α, the monolayer cell cultures of IOSE25
cells were trypsinized. Viable cells were counted by Vi-Cell XR cell
viability analyzer (Beckman Coulter, Miami, FL).
Results
Formation of Spheroids of Normal HOSE Cells in 3D Matrix
To obtain a relevant model for studying the early events of ovarian
cancer, we established a unique 3D in vitro organoid model of normal
HOSE cells. In this model, normal HOSE cells were obtained from
the surface of human ovaries from patients with benign gynecological
diseases. First passages of monolayer culture of primary normal HOSE
cells were harvested for the in vitro organoid model (Figure 1A). To
ensure the quality of epithelial cells in primary cultures, the cell cultures
were immunofluorescent stained with ovarian epithelial markers (cyto-
keratins AE1&3 and calretinin). Normal HOSE cells in primary
cultures presented a compact and cobblestone-like pattern and were
positive for cytokeratins and calretinin (Figure 1B). The primary
cultures with more than 95% of normal HOSE cells were used for
subsequent 3D culture.
For 3D organoid model, single-cell suspension of normal HOSE
cells was seeded onto the matrix. Cell aggregates were formed within
the matrix after 2 days. After the 40-day culture, spheroids of normal
HOSE cells with single epithelial lining and hollow lumen were
formed (Figure 1C ). Using our method, in general, 70% of HOSE
samples from different patients were able to grow spheroids. Approxi-
mately 20 spheroids of normal HOSE cells were formed in each well
of eight-well glass-chambered slides. The sizes of the spheroids varied,
which were dependent on the number of normal HOSE cells aggre-
gated. Most of the normal HOSE cells ended up as constituents of
the spheroids, whereas only a very small amount of cells remained
single in the matrix. In addition, all of the spheroids were found to be
developed with a lumen.
The morphogenesis of spheroids of the normal HOSE cells was
investigated by immunofluorescent staining of a cell proliferation
marker (Ki-67) and an apoptotic marker (active caspase-3). Ki-67–
positive cells were not detected in the spheroids throughout 40-day
culture. This result indicated that normal HOSE cells of the spheroids
are in a growth-arrested status. On the contrary, activated caspase 3–
positive cells were detected in the internal luminal cells but not in
the outer cell layer of the spheroids. This result suggested that apoptosis
contributes to the lumen formation of the spheroids of normal HOSE
cells (Figure 1D).
Besides Ki-67 and activated caspase 3, the morphogenesis of normal
HOSE spheroids was further analyzed by several specific antibodies,
which have been used to characterize the 3D in vitroMCF-10A mam-
mary acini [18]. E-cadherin (ECAD), a protein for cell-cell junctions,
was expressed in the normal HOSE cells of the spheroids at days 2
and 7. However, the expression of ECAD was lost in the epithelium
of spheroids at days 14 and 40. Collagen type IV (COL4), a compo-
nent of basement membrane, was absent in normal HOSE spheroid
at day 2, but COL4 was expressed at basal surface of normal HOSE
spheroids at days 7, 14, and 40. This result indicated that the develop-
ment of basement membrane, which surrounds the spheroid of normal
HOSE cells, is started beyond day 2 of the culture. The ERM proteins
play a role in regulate cell size/shape and are located in actin-rich struc-
tures. At day 2 of the culture, ERM proteins were evenly expressed
in the spheroid of normal HOSE cells. However, the expression of
ERM proteins was distinctively localized at the basal surface of HOSE
spheroids at the culture days 7, 14, and 40 (Figure 2A). The expression
pattern of ERM proteins was similar to that of F-actin during the
development of HOSE spheroids (Figure 1C ). On the basis of the
localizations of ERM proteins and F-actin, our results suggested that
epithelial polarity is established in normal HOSE spheroid during
the morphogenesis.
In Vitro Spheroids of Normal HOSE Cells Resembles In Vivo
Epithelial Inclusion Cyst in Human Ovarian Cortex
The characteristic of mature spheroids of the normal HOSE cells
(day 40) was further examined by TEM and other immunofluorescent
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staining. In semithin section of the spheroid, a single epithelial lining
of flat cells was observed. By TEM, a basement membrane was detected
at the basal surface of the ovarian epithelium (Figure 2B). The base-
ment membranes in the mature spheroids were also shown by basal
expression of COL4 and HSPG. The epithelial lining of the spheroids
was polarized as indicated by apical localization of a Golgi marker
GM130. In addition, epithelium of the mature spheroids maintained
expression of calretinin (Figure 2C).
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Parallel immunofluorescent experiments were performed on the
frozen sections of an in vivo epithelial inclusion cyst in the human
ovarian cortex. The results showed that human ovarian inclusion cyst
was consisted of a single epithelium of flat cells, which expressed
cytokeratins (AE1&3) and calretinin (Figure 2C). GM130 was located
at the apical surface of the epithelium, whereas the components of
basement membrane (laminin V, HSPG, and COL4) were expressed
at the basal surface of the epithelium of ovarian inclusion cyst (Fig-
ure 2C and data not shown). Because the protein expression, locali-
zation, and morphology of in vivo human ovarian inclusion cyst
are similar to those of in vitro normal HOSE spheroids, the results sug-
gested that the normal HOSE spheroid model system resembles in vivo
human ovarian inclusion cysts.
Immortalized HOSE Cell Lines Fail to Form Simple
Spheroids in Matrix
The HPV E6/E7– or hTERT-immortalized HOSE cell lines are
useful nonmalignant tools for the studies of ovarian carcinogenesis
[16,17]. Therefore, we attempted to use these immortalized non-
malignant HOSE cells for the in vitro organoid model. Our results
showed that HPV E6/E7–immortalized cell lines (IHOSE1-15,
IHOSE12, and IHOSE636) failed to form simple spherical struc-
tures in the matrix. They formed disorganized aggregates with irregu-
lar epithelial polarity and mild protrusion instead (Figure 3A). For
hTERT-immortalized HOSE cell lines, three of them (IOSE20C2,
IOSE21C21, and IOSE25C2) formed disorganized structures in
the matrix, whereas the IOSE25C26 cells remained a scattering of
small cell masses in the matrix (Figure 3B).
TNF-α Induces Enlargement of the Spheroids of HOSE
Cells by Reinitiating Proliferation
To investigate the role of inflammatory cytokine TNF-α on malig-
nant transformation of the normal ovarian epithelium, the spheroids
of normal HOSE cells were treated with a protumor dose of TNF-α
(10 ng/ml) for 36 days. After TNF-α treatment, sizes of the treated
cystic structures were significantly larger than that of the control HOSE
spheroids (Figure 4, A and B). MTT assay demonstrated that the cell
proliferation rates of TNF-α–treated cystic structures were significantly
higher than that of the control at culture days 15 and 40, respectively
(Figure 4C ). Positive Ki-67 cells were also detected in TNF-α–treated
cystic structures at day 15 (Figure 4D). These results indicated that
TNF-α causes enlargement of the spheroids by reinitiating prolifera-
tion. This TNF-α–induced cell proliferation was also correlated with
the up-regulation of a protumor cytokine, IL-1β, in the TNF-α–treated
cystic structures (Figure 4E).
TNF-α Induces Disorganization, Multilayer Stratification,
Disruption of Epithelial Polarity, and Disintegration of
Basement Membrane in Ovarian Epithelial Cystic Structures
By immunofluorescent staining of ERM proteins, disorganization
andmultilayer stratification in theTNF-α–treated cystic structures were
observed. Moreover, the expression of ERM proteins in the TNF-α–
treated cystic structures was not restricted at the basal surface but spread
throughout the structures (Figure 4F). Expression of GM130 was also
no longer restricted at the apical surface of the TNF-α–treated cystic
structures (Figure 5B). These results suggested that TNF-α induces dis-
ruption of epithelial polarity in the cystic structures. In addition, the
expressions of COL4 (Figure 5A) and HSPG (Figure 5B) at the basal
surface of the cystic structures were significantly lost after TNF-α treat-
ment. These results suggested that TNF-α induces disintegration of
basement membrane in ovarian epithelial cystic structures. The loss of
basement membrane in the TNF-α–treated cystic structures was corre-
lated with the down-regulation of transcript level of COL4 (COL4A1;
Figure 5B).
Because basement membranes are degraded by MMPs in tumor
progression, we compared the expression levels of MMP and TIMP
genes in control HOSE spheroids and TNF-α–treated cystic structures.
Our result demonstrated that messenger RNA (mRNA) and protein
expressions of MMP-10 (stromelysin 2) were significantly higher in
the TNF-α–treated cystic structures when compared with the normal
control (Figure 5, C and D). This result suggested that the basement
membrane of HOSE spheroid may be disintegrated by MMP-10
during TNF-α treatment.
TNF-α Induces Invasive Phenotype in Ovarian Epithelial
Cystic Structures
After TNF-α treatment, expression of F-actin was no longer con-
fined at the basal surface of the cystic structure. Actin rearrangement
and cellular protrusion were found in TNF-α–treated cystic structures
instead (Figure 6A). These observations indicated that TNF-α induces
invasive phenotype in the cystic structures. Because chemokine recep-
tor CXCR4 is critical to tumor cell migration and is regulated by
TNF-α in ovarian cancer cells [20], we examined the mRNA expres-
sion of CXCR4 in the cystic structures after TNF-α treatment. Up-
regulation of CXCR4 transcript was found in TNF-α–treated cystic
structures when compared with the control HOSE spheroids (Fig-
ure 6B). These results suggested that TNF-α upregulates CXCR4
in the ovarian epithelial cells and promoted cell migration from the
ovarian cystic structures to extracellular matrix.
Although the E6/E7–immortalized HOSE cells did not form simple
spherical structures in the control experiments (Figure 3A), TNF-α also
induced larger, prominently disorganized and extensive invasive pheno-
types in the in vitro organoid model of E6/E7–immortalized HOSE
Figure 1. In vitro organoid model of normal HOSE cells. (A) Schematic diagram to show the experimental procedure of the in vitro
organoid model of normal HOSE cells. Normal HOSE cells were obtained by cytobrushing the surface epithelium (S) of normal ovary
and were subsequently cultured. First passages of the primary cultures of normal HOSE cells were harvested for 3D in vitro cultures. (B)
Phase-contrast images of three representative monolayer cultures of primary normal HOSE cells (a); Immunofluorescent staining of
cytokeratin (AE1&3) and calretinin in monolayer cultures of primary normal HOSE cells (b). (C) Morphogenesis of spheroids of normal
HOSE cells in 3D matrix. Upper panel: phase-contrast images of aggregates and spheroids of normal HOSE cells at different stages of
in vitro organoid model. Middle panel: fluorescence staining of F-actin and nuclei in aggregates and spheroids of normal HOSE cells at
different stages of the culture; F-actin proteins were stained by phalloidin, whereas nuclei were stained by DAPI. Lower panel: sche-
matic diagram of the morphogenesis of the spheroids of normal HOSE cells. (D) Immunofluorescent staining of Ki-67 (a) and activated
caspase 3 (b; Casp-3) at different stages of the morphogenesis of spheroids of normal HOSE cells; nuclei were counterstained by DAPI.
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Figure 2. Characterization of the spheroids of normal HOSE cells in the matrix. (A) Immunofluorescent staining of ECAD (upper row),
COL4 (middle row), and ERM (lower row) at different stages of the morphogenesis of spheroids of normal HOSE cells; nuclei were
counterstained by DAPI. (B) Semithin section of the spheroid of normal HOSE cells in the Matrigel (a). ECM indicates extracellular
matrix; Ep, epithelial lining; Lu, lumen of spheroid. Transmission electron microscopic imaging of the spheroid of normal HOSE cells (b).
BM indicates basement membrane (arrow); ECM, extracellular matrix. (C) Upper panel: immunofluorescent staining of GM130, COL4,
HSPG, and calretinin of in vitro normal HOSE spheroids. Lower panel: immunofluorescent staining of GM130, laminin V (LamV), HSPG,
cytokeratin (AE1&3), and calretinin of an in vivo ovarian inclusion cyst.
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cells (Figure 6C). Taken together, these results indicated that TNF-α
induces cell migration and invasion of ovarian epithelial cells of the
cystic structures.
TNF-α Upregulates Ovarian Cancer Markers in Ovarian
Epithelial Cystic Structures
The overexpression of ovarian cancer markers (CA125, MUC1,
EpCAM, and claudin 4) was detected in the TNF-α–treated ovarian
cystic structures when compared with the control HOSE spheroids
(Figure 6D).
Collectively, our results demonstrated that the TNF-α–treated cystic
structures exhibit characteristics of precancerous ovarian lesions.
TNF-α Fails to Induce Cell Proliferation in Monolayer
Culture of Immortalized HOSE Cells
To study the effect of TNF-α on monolayer cell culture of HOSE
cells, we treated the monolayer cell culture of IOSE25 cells with
TNF-α (10 ng/ml) for 5 days. Cell viability and CXCR4 expression
were examined after the treatment. Up-regulation of CXCR4 was de-
tected in monolayer cell culture of IOSE25 cells after treatment with
TNF-α; however, no TNF-α–induced cell proliferation could be
found in monolayer cell cultures of IOSE25 cells (Figure 6E ). The
discrepancy between the monolayer cell culture and the spheroid
culture model suggested that the latter is a better model as a precursor
of ovarian cancer.
Discussion
In the present study, we established an organoid model of normal
HOSE cells, which recapitulates the epithelial inclusion cyst in human
ovarian cortex. The resemblance of this in vitro organoid model to an
epithelial inclusion cyst constitutes a useful tool for investigating the
roles of oncogenes, tumor suppressors, and extrinsic factors for ovarian
tumor development.
Figure 3. Three-dimensional in vitro culture of immortalized HOSE cells. (A) Three-dimensional in vitro organoid model of HPV E6/E7–
immortalized HOSE cells. Upper panel: phase-contrast images of the cystic structures of E6/E7–immortalized HOSE cells in the matrix.
Lower panel: fluorescence staining of F-actin and nuclei in the cystic structures of E6/E7–immortalized HOSE cells. (B) Phase-contrast
images of 3D in vitro cultures of hTERT-immortalized HOSE cells in the matrix.
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Figure 4. Tumor necrosis factor α induced enlargement, disorganization, multilayer stratification, and disruption of cell polarity in ovarian
epithelial cystic structures. (A) Representative phase-contrast images of normal HOSE spheroids and TNF-α–treated cystic structures at
culture day 40. Scale bar, 20 μm. (B) Statistical analysis of diameters (in μm) of control HOSE spheroids (n = 55) and TNF-α–treated
cystic structures (n = 59) at day 40. The box is bounded above and below by the 75th and 25th percentiles; the median is indicated by
the line in the box. Statistical analysis was performed using nonparametric Mann-Whitney U test. (C) MTT assay of control HOSE spheroids
and TNF-α–treated cystic structures at culture days 7, 15, and 40. The cell proliferation rate of the TNF-α–treated group was normalized to
that of the control group. Bars, SE. (D) Immunofluorescent staining of Ki-67 in TNF-α–treated cystic structures at day 15: DAPI stain (left) and
Ki67 immunostaining (right). (E) Quantitative RT-PCR analysis of IL-1β gene in control HOSE spheroids and TNF-α–treated cystic structures at
day 40. The transcript level of the target genes in TNF-α–treated cystic structures was normalized to that in the control HOSE spheroids
using 2(−ΔΔCT) calculation. (F) Immunofluorescent staining of ERM in control HOSE spheroids and TNF-α–treated cystic structures at day 40;
four representative images of each treatment are shown.
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Figure 5. Tumor necrosis factor α induced disintegration of basement membrane and expression of MMP-10 in ovarian epithelial cystic
structures. (A) Immunofluorescent staining of COL4 in control HOSE spheroids and TNF-α–treated cystic structures at day 40; four
representative images of each treatment are shown. (B) Left panel: immunofluorescent staining of HSPG and GM130 in TNF-α–treated
cystic structures at day 40. Right panel: quantitative RT-PCR analysis of COL4 (COL4A1) gene in control HOSE spheroids and TNF-α–
treated cystic structures at day 40. The transcript level of the target genes in TNF-α–treated cystic structure was normalized to that in the
control HOSE spheroids using 2(−ΔΔCT) calculation. (C) Semiquantitative RT-PCR analysis of MMP and TIMP genes in control HOSE
spheroids and TNF-α–treated cystic structures at day 40. Expression of GAPD was served as control of mRNA input. (D) Up-regulation
of MMP-10 in TNF-α treatment of the HOSE spheroids. Left panel: quantitative RT-PCR analysis of MMP-10 gene in control HOSE
spheroids and TNF-α–treated cystic structures at day 40. Right panel: representative results of immunofluorescent staining of MMP-
10 protein in control HOSE spheroids and TNF-α–treated cystic structures at day 40.
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The formation of epithelial inclusion cysts in vivo is not fully un-
derstood. The proposed origins of the epithelial inclusion cysts are
the fragments of OSE, which are trapped in or near ruptured follicles
at the time of ovulation [21,22], or invaginations of the OSE into the
stroma of the ovary as a result of ovulation and aging [5]. The his-
tologic diagnosis of OSE cells lining the regularly shaped inclusion
cysts in vivo was flat to cuboidal [23], which is similar to that of
the spheroids of normal HOSE cells in our organoid model. On
the contrary, the population of OSE cells in irregularly shaped inclu-
sion cysts in vivo was heterogeneous, i.e., a combination of normal
flat-to-cuboidal OSE cells, columnar OSE cells, and intermediate
stages between cuboidal and columnar types of OSE cells was ob-
served [23]. Such irregularly shaped inclusion cysts were often found
in ovarian tissues obtained from patients undergoing oophorectomy
for genital tract pathology and from patients with a family history of
breast and/or ovarian cancer [23]. These observations highly sug-
gested that the irregularly shaped inclusion cysts in vivo are the pre-
cancerous (dysplastic) lesions of ovarian epithelial malignancy [24].
Ovarian epithelial dysplasia was first described after prophylactic
oophorectomies for genetic risk. Ovarian dysplasia in epithelial inclu-
sion cysts of the high-risk population has also been described [24–26].
In a previous study, the normal identical twin sisters of the patients with
ovarian cancer were subjected to prophylactic oophorectomy after
menopause. Histological examination of these ovarian tissues revealed
dysplastic changes in epithelial inclusion cysts, including transition of
epithelial inclusion cysts from cuboidal to tall columnar ciliated epithe-
lium, cellular stratification, loss of polarity, and epithelial tufting [26].
The finding of epithelial abnormality suggested a precancerous change
in epithelial inclusion cysts similar to other genital epithelial dysplasia
[24,26]. Several other cancerous features, such as loss of basement
membrane, loss of Dab-2 expression, overexpression of Cox-2, Ki-67,
and tumor markers, were also detected in epithelial inclusion cysts of
the high-risk patients [23,27,28]. Taken together, these results sug-
gested that the precancerous lesion might arise at the epithelial inclusion
cysts, which have been exposed to the stimuli of ovarian stromal micro-
environment [29]. Although two recent reviews have suggested that
fallopian tube fimbria is a field of origin for high-grade serous carcinoma
of the ovary as well as ovarian epithelial tumors that arose from tissues
that are embryonically derived from the müllerian ducts (i.e., fallopian
tubes, endometrium, and endocervix) [30,31], we cannot rule out the
fact that OSE cells are one of the cell origins of ovarian epithelial cancer.
More interestingly, the TNF-α–treated ovarian cystic structures in
our experiment shared the similarities (i.e., epithelial stratification,
loss of epithelial polarity, loss of basement membrane, loss of Dab-2
expression, overexpression of Ki-67, overexpression of Cox-2, and over-
expression of tumor markers) that are found in the ovarian dysplasia of
epithelial inclusion cysts of the high-risk patients. These similarities
suggest that the TNF-α–treated ovarian cystic structures exhibit charac-
teristics of precancerous lesions of ovarian epithelial malignancy.
Tumor necrosis factor α (TNF-α) was originally identified and
characterized by its ability to induce necrosis in tumor with high-dose
administration [32,33]. Follow-up studies demonstrated that sustained
production of TNF-α in the tumor microenvironment could promote
progression of tumor cells [34–37]. It has also been shown that TNF-α
is a potent tumor promoter in BALB/3T3 cell transformation during
cotreating the cells with the chemical carcinogen 3-methylcholanthrene
and TNF-α [38]. Other studies using mice deficient in TNF-α showed
that TNF-α could promote the progression of skin carcinogenesis
induced by carcinogen [39–41], whereas its molecular actions in such
tumor progression included 1) induction of DNA damage and subse-
quent gene mutations by increasing reactive oxygen species [42,43], 2)
stimulation of epithelial-to-mesenchymal transition by activating p38
MAPK andERK activity [44], 3) induction of invasiveness and adhesion
of the epithelial cells by enhancing the expression of MMP-9 and α2
integrin [45], and 4) enhancement of metastasis of tumor cells [46–49].
Tumor necrosis factor α plays a role in ovarian cancer has been
known for more than two decades. Tumor necrosis factor α and its re-
ceptors are expressed in human ovarian cancers [50]. Studies showed
that TNF-α induced autocrine production of TNF-α and cell growth
in OSE cells [14,51,52]. However, when we treated the monolayer cell
culture of immortalized HOSE cells with TNF-α, no TNF-α–induced
cell proliferation was found in the monolayer cultures of immortalized
HOSE cells. The discrepancy between these studies may be due to the
difference in doses of TNF-α for in vitro treatments. Yang et al. [13]
reported that treatment of TNF-α in immortalized HOSE cells would
degrade the components of basement membrane (COL4 and laminin)
through increasing the activity of urokinase-type plasminogen activator
and MMP-9. However, no study has yet been reported that TNF-α
could confer malignant transformation in normal HOSE cells. In
ovarian cancer cells, TNF-α upregulated the expression of chemokine
receptor CXCR4 through activating the components of the NF-κB
pathway [20]. Furthermore, knockdown of TNF-α in ovarian cancer
cells reduced the production of tumor-promoting cytokines and
chemokines, tumor growth and metastasis, growth of endothelial cells,
and vascularization of the tumor [15]. Taken together, TNF-α may
enhance tumor growth and invasion by inducing the secretion of cyto-
kines, proangiogenic factors, and metalloproteinases.
The results of these basic medical research encouraged phase 1 clini-
cal studies on the treatment of ovarian cancer with TNF-α inhibitors.
Thalidomide is a drug that inhibits the processing of the mRNA of a
number of peptide-signaling molecules such as TNF-α. The use of
thalidomide was investigated in 19 patients with ovarian cancer. One
of the patients experienced stabilization of disease for more than
3 months [53]. Etanercept is a recombinant human soluble p75 TNF
Figure 6. Tumor necrosis factor α induced invasive phenotypes and overexpression of ovarian cancer markers in ovarian epithelial cystic
structures. (A) Fluorescence labeling of F-actin (phalloidin) and nuclei (DAPI) in control HOSE spheroids and TNF-α–treated cystic structures
at day 40; four representative images of each treatment are shown. (B) Quantitative RT-PCR analysis of CXCR4 in control HOSE spheroids
and TNF-α–treated cystic structures at day 40. (C) Tumor necrosis factor α treatment on the cystic structures of HPV E6/E7–immortalized
HOSE cells in the matrix for 30 days. Upper panel: phase-contrast images of the cystic structures of E6/E7–immortalized HOSE cells after
TNF-α treatment. Lower panel: fluorescence staining of F-actin (phalloidin) and nuclei (DAPI) of the cystic structures after TNF-α treatment.
(D) Immunofluorescent staining of ovarian cancer markers (CA125, MUC1, EpCAM, and claudin 4) in control HOSE spheroids and TNF-α–
treated cystic structures at day 40. (E) Left panel: cell viability assay in IOSE25 cells in the presence of TNF-α (0 and 10 ng/ml) for 1, 3, and
5 days. Right panel: quantitative RT-PCR of CXCR4 in IOSE25 cells in the presence of TNF-α (0 and 10 ng/ml) for 1, 3, and 5 days. Bars, SE.
ns indicates not significant. ***Statistically significant as analyzed by repeated ANOVA.
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receptor that binds to TNF-α. Treatment with etanercept has been
investigated in 30 patients with recurrent ovarian cancer. Eighteen of
the 30 patients completed the treatment. Six patients achieved pro-
longed disease stabilization, and a significant rise in immunoreactive
TNF-α was seen in all patients [54]. These results indicated that the
effect of the TNF-α inhibitors is limited in ovarian cancer treatment.
The reason may be that the inhibition of TNF-α is compensated by
other members in cytokine network of ovarian tumor microenviron-
ment [15].
This report has mainly investigated the role of TNF-α in tumor
initiation from the organoid model of normal HOSE cells. Our results
demonstrated that TNF-α conferred precancerous phenotype in the
normal HOSE spheroids. These data further supported the link
between chronic inflammation and ovarian carcinogenesis, particularly
in tumor initiation, and illustrated that this precancerous phenotype is
arisen from the site mimicking the epithelial inclusion cysts. However,
our results also reflected that TNF-α alone could not completely trans-
form the normal HOSE cells to malignant phenotypes. In this case,
we suggest that other protumor cytokines, such as IL-1β and IL-6,
are needed for the malignant transformation of normal HOSE cells.
It is also possible that cellular senescence would occur in the TNF-
α–treated ovarian cystic structures if there are any DNA damage and
oncogenic signals in HOSE cells, which are induced by the cytokine.
Because cells enter senescence in response to a variety of cellular stress,
including telomere erosion, DNA damage, and oncogenic signals, cellu-
lar senescence could act as a barrier against malignant transformation.
If this happens, it will be another reason why TNF-α alone could not
induce malignant transformation of normal HOSE cells. Indeed, cellu-
lar senescence is frequently present in precancerous lesion of tumors
[55]. Therefore, a future study is needed to investigate whether
TNF-α could induce cellular senescence in the HOSE spheroids.
Besides, it is commonly known that tumor mass is not solely com-
posed of tumor cells; the microenvironment of tumor consists of dif-
ferent cell types. Because tumor microenvironment would influence
tumor progression and metastasis, lack of stromal components (e.g.,
fibroblasts) in the 3D organoid model may be a factor that contributes
to the failed transformation of normal HOSE cells.
In summary, we believe that our organoid model of normal HOSE
cells is a relevant model for ovarian cancer research because the epithelial
inclusion cysts are thought to be the site of origin of the disease [6,56].
More importantly, this model may be very useful in studying the
pathogenesis of ovarian cancer, and the results indicate that inflamma-
tion may be important in ovarian carcinogenesis.
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